Gastroenterology
Long-term Outcomes of Neoadjuvant Nivolumab and Ipilimumab in MSI-High Gastric and GEJ Adenocarcinoma: Insights from the Phase 2 NEONIPIGA Trial
The NEONIPIGA phase 2 trial demonstrates durable survival and high pathological complete response rates with neoadjuvant nivolumab and ipilimumab in localized MSI-high gastric and GEJ adenocarcinoma, highlighting potential for organ-preserv
